Contribution of intangible costs to the economic burden of multiple sclerosis

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 626-632

  Wundes, Annette ^a   Brown, Theodore ^b   Bienen, E Jay ^c   Coleman, Craig I ^d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Evergreen Hospital Medical Center   (United States)

^c Curry Rockefeller Group   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

health care costs; intangible costs; multiple sclerosis; quality of life; quality adjusted life years; willingness to pay

Indexed keywords

DISABILITY; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDLINE; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ADULT; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 78650057763     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.525989     Document Type: Review

References (46)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952
2. Johansson S, Ytterberg C, Claesson IM, et al. High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol 2007;254:767-773
3. Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 2006;12:620-628
4. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-98
5. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: A review of literature. Mult Scler 2005;11:232-239
6. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional study in the United States. Neurology 2006;66:1696-1702
7. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-926
8. McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: Service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847-860
9. Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: Extrapolations from a multinational cost study. Mult Scler 2007;13: 1054-1064
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
11. Kurtzke JF, Wallin MT. Epidemiology. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos, 2000:49-71
12. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-994
13. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146
14. Multiple Sclerosis: Hope Through Research. National Institute of Neurological Disorders and Stroke. Bethesda, MD. Updated April 28, 2010. Available at: www.ninds.nih.gov/disorders/multiplesclerosis/detail-multiple- sclerosis. htm#153333215 [Last accessed 1 July 2010]
15. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425
16. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford University Press, 1997
17. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: Data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30:233-267
18. Nortvedt MW, Riise T, Myhr KM, et al. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098-1103
19. Solari A, Radice D. Health status of people with multiple sclerosis: A community mail survey. Neurol Sci 2001;22:307-315
20. Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? Q J Med 2004;97:671-676
21. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003;9:63-72
22. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: A community health survey. Health Qual Life Outcomes 2008;6:1
23. Casado V, Romero L, Giubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler 2007;13:800-804
24. The EuroQol Group. EuroQol - a new facility for the measurement of healthrelated quality of life. The EuroQol Group. Health Policy 1990;16:199-208
25. Gold MR, Siegel JE, Russell LB, et al., eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996
26. CHOosing Interventions that are Cost Effective (WHO-CHOICE). World Health Organization (WHO), Geneva, Switzerland, 2010. Available at: www.who.int/ choice/costs/CER-thresholds/en/index.html [Last accessed 1 July 2010]
27. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7:S55-64
28. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7(Suppl 2):S45-54
29. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7(Suppl 2):S14-23
30. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7(Suppl 2):S34-44
31. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7(Suppl 2):S24-33
32. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006;7(Suppl 2):S86-95
33. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7(Suppl 2):S65-74
34. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(Suppl 2):S75-85
35. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(Suppl 2):S96-104
36. Henriksson F, Fredrikson S, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis - a population-based cross-sectional study in Sweden. Stockholm: Stockholm School of Economics; 2000 SSE/EFI Working Paper Series in Economics and Finance, March. Report No. 361
37. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
38. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. a cross-sectional observational study in the UK. Stockholm: Stockholm School of Economics; 2000 SSE/EFI Working Paper Series in Economics and Finance. Report No. 398
39. Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: A systematic review of the literature. J Med Econ 2010;13:78-89
40. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. Discussion Paper #172. University of York Centre for Health Economics, York, UK, 1999. Available at: www.york.ac.uk/inst/che/pdf/DP172.pdf [Last accessed 1 July 2010]
41. Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: A systematic review of the literature. Pharmacoeconomics 2010;28:363-379
42. Gyrd-Hansen D. Willingness to pay for a QALY: Theoretical and methodological issues. Pharmacoeconomics 2005;23:423-432
43. King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life-year: Implications for societal health care resource allocation. Med Decis Making 2005;25:667-677
44. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? [commentary]. Arch Intern Med 2003; 163:1637-1641
45. Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356
46. Lee CP, Chertow G, Zenios SA. An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 2009; 12:80-87